U.S., Aug. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07775703) titled 'HS-20117-2 Injection in Patients With Advanced Solid Tumors' on Nov. 19, 2025.

Brief Summary: This trial is a multicenter, open-label, Phase I clinical study designed to evaluate the pharmacokinetics, safety, and tolerability of HS-20117-2 in patients with advanced solid tumors.

Study Start Date: Nov. 13, 2025

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumors

Intervention: DRUG: HS-20117-2 Injection

Participants will receive subcutaneous injections of HS-20117-2 Injection

Recruitment Status: RECRUITING

Sponsor: Hansoh BioMedical R&D Company

Published by HT Digital Content Services with permission from Health Dail...